Samsung and Alcedis will explore how Galaxy Watch biometric data can support clinical trials, digital endpoints, and drug research.
The collaboration focuses on leveraging the sensor array found in modern Samsung Galaxy Watch devices to provide continuous health tracking for participants enrolled in clinical studies. This move aligns with broader industry trends toward decentralized clinical trials, where remote monitoring plays an increasingly central role in drug development pipelines.
How Galaxy Watch Biometric Data Supports Clinical Research
The core of the initiative involves using the Galaxy Watch to track specific health markers that can serve as digital endpoints in a research environment. Digital endpoints are objective, quantifiable physiological and behavioral data collected by means of digital health technologies, which are used to measure the efficacy or safety of a medical intervention.
Samsung’s hardware provides a constant stream of data that was previously difficult to capture. By working with Alcedis, Samsung is positioning its consumer hardware to meet the requirements necessary for pharmaceutical-grade research. The integration is expected to allow researchers to observe how a drug affects a patient’s daily activity levels or sleep quality, providing insights that are often missed during sporadic, in-person check-ups.
The adoption of wearable technology in clinical research is part of a wider industry shift toward decentralized clinical trials (DCTs). By moving data collection to a wearable device, researchers can include a more diverse patient population, which is a key priority for global health initiatives.
Alcedis will act as the bridge between the raw data generated by the Galaxy Watch and the analytical needs of clinical investigators. This partnership follows a period of rapid innovation in wearable health tech.
Why Digital Endpoints Matter for Drug Development
Integrating wearable data into clinical trials is not merely about convenience; it is about gathering higher-quality evidence. Traditional clinical trials often rely on “snapshot” data—measurements taken only when a patient is in the clinic. However, health markers such as heart rate variability or nocturnal movement can fluctuate significantly throughout the day.
By utilizing the Galaxy Watch, researchers can potentially shorten the time required to gather sufficient evidence for a new drug, as the data density is far higher than that of traditional paper-based or manual reporting methods.
What Happens Next in the Samsung-Alcedis Partnership
The partnership between Samsung and Alcedis is currently in the exploratory and integration phase. As the two companies work to standardize the data flow from the Galaxy Watch into clinical trial management systems, they are expected to refine the specific biometric metrics that will be used for upcoming studies. While no specific drug trials have been announced under this partnership, the infrastructure being built is designed to be scalable across various therapeutic areas.
Future updates are expected as the companies begin to deploy these wearable-integrated trials in real-world settings. Readers interested in the evolution of digital health and clinical trial innovation are encouraged to monitor future announcements from both Samsung and Alcedis for upcoming trial protocols and methodology disclosures.
Do you believe wearable data will replace traditional in-clinic testing? Share your thoughts in the comments below.